ABOUT US

Making genetic medicine accessible for all

Interius BioTherapeutics is a clinical-stage biotechnology company working to expand the potential and reach of genetic medicine by developing next-generation delivery technology. Our multidisciplinary team brings deep scientific understanding and industry experience guiding multiple programs from discovery to commercialization. By lifting the barriers between genetic medicines and patients in need, we are poised to deliver first-in-class and best-in-class therapies to millions of people quickly and at scale.

Leadership

Phil Johnson, MD

President and Chief Executive Officer

Dora Mitchell, PhD

Senior Vice President, Operations and Chief of Staff

Tim Culp, PhD

Vice President, Research and Development

Jessica Imrie, MBA

Vice President, Portfolio and Program Development

James Richardson, PhD

Senior Director, Analytical Development

Bruce Schnepp, PhD

Senior Director, Discovery

James Andorko, PhD

Director, Discovery

Scott J. Dooley, PhD

Director, Intellectual Capital

Patricia Greeley, SHRM-SCP

Director, Human Resources

Babu Medi, BPharm, PhD

Senior Director, Drug Product Development

Sianny Christanti

Senior Director, Process Development

Lovisha Love-Diggs, CPA, MS

Finance Controller

Matt Troutman

Director, High Throughput Screening and Analytics (HTSA)

Advisors

Bruce Peacock

Founder

Saar Gill, MD, PhD

Founder, SAB Chair

Richard Peluso, PhD

Key Scientific Advisor, Virology, Vectors, & Manufacturing

Mike Betts, PhD

Key Scientific Advisor, Human & Monkey Immunology

Jim Ackland

Global Regulatory Affairs

Erika De Boever, DDS MPH PhD

Clinical Development Scientist

Emberly Dumayas

Clinical Operations Leader

Elizabeth Tarka, MD

Clinical Development Physician

CLINICAL ADVISORY BOARD

Jeremy S. Abramson, MD

Massachusetts General Hospital, Harvard Medical School

Michael Dickinson, MBBS, D Med Sc, FRACP, FRCPA

Peter MacCallum Cancer Centre and Royal Melbourne Hospital

David G. Maloney, MD, PhD

Fred Hutch Cancer Center

Loretta J. Nastoupil, MD

MD Anderson Cancer Center

Marion Subklewe, MD, PhD

Gene Center and Ludwig Maximillian University of Munich

BOARD OF DIRECTORS

Lonnie Moulder

Board Chairman

Phil Johnson, MD

President and Chief Executive Officer

Bihua Chen

Director

Tomas Kiselak

Director

Michael C. Diem, MD

Director

Partner with us

As part of our work to deliver best-in-class genetic medicines to patients, we welcome the opportunity to talk with potential partners worldwide about licensing relationships and collaborations across a range of therapeutic areas.